AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) Has Increase in Shorts

July 26, 2017 - By Marguerite Chambers

The stock of AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) registered an increase of 29000% in short interest. AMBS’s total short interest was 29,100 shares in July as published by FINRA. Its up 29000% from 100 shares, reported previously. With 452,500 shares average volume, it will take short sellers 0 days to cover their AMBS’s short positions.

It closed at $0.031 lastly. It is down 0.00% since July 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The company has market cap of $2.00 million. The Firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It currently has negative earnings. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry.

More notable recent Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) news were published by: Usmarketsdaily.com which released: “AMARANTUS BIOSCIENCE HOLDINGS, INC. (OTCBB:AMBS) Pays $2.3 Million In Final …” on March 06, 2015, also Prnewswire.com with their article: “Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience …” published on November 19, 2014, Marketwatch.com published: “0.031” on June 30, 2011. More interesting news about Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) were released by: Globenewswire.com and their article: “Amarantus Effects Capital Restructuring in Anticipation of National Exchange …” published on May 22, 2015 as well as Seekingalpha.com‘s news article titled: “Amarantus’ LymPro Could Be A Game-Changer For Alzheimer’s Diagnosis” with publication date: April 17, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.